Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and … (NCT02602600) | Clinical Trial Compass
CompletedPhase 4
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
Denmark33 participantsStarted 2015-11-19
Plain-language summary
The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.
Who can participate
Age range
40 Years – 75 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
* Women aged 40-75 with angina-like symptoms assessed by the Seattle Angina Questionnaire (SAQ).
* Referred for ischemic heart disease (IHD) assessment with no significant coronary stenosis (\>50%) at coronary angiography or CT-angiography
* Impaired CFR assessed by echo Doppler flow (defined ratio≤2,5).
* BMI≥25kg/m2
Exclusion Criteria:
* Allergy to dipyridamole, theophyllamine or liraglutide
* Previous myocardial infarction or revascularization
* No episodes of chest pain within 6 months before inclusion
* Diabetes (reported, noted in journal or patient on antidiabetic medication)
* Other causes of chest discomfort deemed highly likely
* Left ventricular ejection fraction \<45
* Significant valvular disease
* Congenital heart disease
* severe co-morbidity with limited life-expectancy\< 1 year
* Severe asthma
* Severe chronic obstructive pulmonary disease
* Pregnancy (pregnancy test will be done at inclusion)
* No use of contraception although in child-bearing age. A woman is regarded fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. The birth control methods considered safe and effective includes combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intrava…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change from baseline in Coronary Flow Reserve
Timeframe: Assessed at baseline, week 4 and week 18
2
Change from baseline in Angina Symptoms
Timeframe: Assessed at baseline, week 4 and week 18